Nuclear gamma cameras are a very important imaging modality for molecular imaging and their strength lies mainly in the large global installed base and the availability of longer half-life radioisotopes such as Technetium-99m (with a half-life of 6 hours). However, robust market growth is expected to depend on the development of novel diagnostic and therapeutic imaging agents. In the face of increasing competition for budget/resources from positron emission tomography (PET), new imaging agents can create fresh clinical applications for gamma cameras and help expand the market.
